Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 55 bp deletion in exon1 and 73 bp deletion in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-EMC10, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The C19orf63 protein also known as MRG domain-binding protein (MRGBP) works mechanically as a component of the histone acetyltransferase complex. It weighs approximately 19 kDa and is expressed in various human tissues with notable expression in HeLa cells. This protein is integral to chromatin modifications influencing transcription regulation through histone acetylation.
Biological function summary
C19orf63 interacts within the histone acetyltransferase complex playing a role in the modification of chromatin structure. It participates in transcriptional regulation by modulating the acetylation state of histones thereby impacting gene expression. This protein does not work alone and requires interaction with other proteins to execute its function efficiently.
Pathways
C19orf63 operates in pathways related to chromatin modification and transcription control. The protein influences the regulation of transcriptional signaling pathways such as the acetylation-dependent signaling pathway. C19orf63 associates with proteins like PCAF a known histone acetyltransferase working together to maintain gene accessibility and transcription fidelity.
C19orf63 has connections with certain cancers through its role in chromatin structure and function alteration. Abnormal expression of this protein might contribute to tumorigenesis by altering gene expression profiles. Through the histone modification pathway it connects with proteins like BRCA1 which is involved in DNA repair and is associated with breast cancer.
